Garcia-Pavia P, Rapezzi C, Adler Y, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2021;42(16):1554-1568. doi:10.1093/eurheartj/ehab072

Kittleson MM, Ruberg FL, et al. 2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis. J Am Coll Cardiol. 2023;81(11):1076-1126. doi:10.1016/j.jacc.2022.11.022

Oghina S, et al., Les amyloses cardiaques : état de lieux en 2022, Rev Med Interne, https://doi.org/10.1016/j.revmed.2022.04.036

Filière Cardiogen & Centre de référence Amyloses Cardiaques, Synthèse à destination du médecin traitant: protocole national de diagnostic et de soins Amylose Cardiaques, HAS, 2021 avril. Accessed June 16, 2023. https://www.has-sante.fr/upload/docs/application/pdf/2021-12/synthese_mg_amylose_cardiaque.pdf

Pathophysiology and Therapeutic Approaches to Cardiac Amyloidosis | Circulation Research. Accessed June 27, 2023. https://www.ahajournals.org/doi/10.1161/CIRCRESAHA.121.318187?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

Centre national de référence Amylose AL, Protocole national de soins Amylose AL 2023, HAS, 2023 fevrier. Accessed Auguste 23, 2023. https://www.has-sante.fr/upload/docs/application/pdf/2022-11/protocole_national_de_diagnostic_et_de_soins_v9.pdf

Triptyque, Amyloses Cardiaques, Réseau Amylose 2021. Accessed June 15, 2023. https://reseau-amylose.org/jesuissoignant/storage/sites/5/2021/12/TRIPTYQUE-Nationalmédecins-2021-1.pdf

Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med. 2018;379(11):1007-1016. doi:10.1056/NEJMoa1805689

Meier C, Yilmaz A, Diagnostik der kardialen Amyloidose, Innere Medizin 2023;64:830-841. doi:10.1007/s00108-023-01571-5